FAS: FOR FURTHER DEVELOPMENT OF THE PHARMACEUTICAL MARKET, IT IS NECESSARY TO INCREASE ITS COMPETITIVENESS

For this purpose, it is necessary to ensure the interchangeability of drugs

Timofey Nizhegorodtsev, Deputy Head of the FAS Russia, took part in the VI Annual Forum “Biotehmed”, one of the key topics of which was Pharmaceutical Market Development Strategy until 2030 (“Pharma 2030” strategy).

According to the representative of the service, in the “Pharma 2030” strategy, it is also necessary to work out in detail the regulation of the circulation of drugs after their registration:

“For the implementation of the strategy, the non-discriminatory presence of Russian medicines in the public procurement process is necessary. Otherwise, it is possible to return to the situation of 10 years ago, when the volume of purchases of domestic drugs was relatively small.”

Timofey Nizhegorodtsev noted that in the National Plan for the Development of Competition, adopted by the Government of the Russian Federation for 2021-2025, measures are planned to achieve the goals of interchangeability of drugs in the pharmaceutical market, while it is important to include them in the Pharma 2030 strategy:

“The interchangeability of medicines both in the line of “One international nonproprietary name (INN) – several manufacturers” and in the line of “Different INN – one therapeutic goal” is a key factor in the sustainable development of the Russian pharmaceutical market and the achievement of the goals of “Pharma 2030.”

Also, according to the FAS Russia, to increase competitiveness, it is necessary to provide accelerated access to the Russian pharmaceutical market for innovative drugs, to reconfigure the work to update the Clinical Guidelines*, to harmonize and synchronize all regulatory procedures for handling drugs with international standards as much as possible. Timofey Nizhegorodtsev proposed to create a project committee, which will include the Ministry of Health, the Ministry of Industry and Trade and the FAS Russia.

The Ministry of Industry and Trade and drug manufacturers supported the initiatives of the Antimonopoly Service. The proposals voiced by the FAS Russia will be considered in detail and included in the “Pharma 2030” strategy.

For reference:

*Clinical guidelines are documents that provide structured information based on scientific evidence on prevention, diagnosis, treatment and rehabilitation.

Photo is provided by the press service of BIOTECHMED.